MDGL News and Press, Madrigal Pharmaceuticals Inc. From 05/21/24

2024-05-21 09:45:00 ET Madrigal Pharmaceuticals ' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezd...

2024-05-16 08:21:28 ET Paulson & Co., the hedge fund founded by John Paulson, increased its stakes in NovaGold ( NG ) to 27.24M from 23.54M shares, International Tower Hill Mines ( THM ) to 64.2M from 61.93M shares and Madrigal Pharmaceuticals (NASDAQ:MDGL) during Q1, accordin...

2024-05-07 11:56:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Madrigal Pharmaceuticals (NASDAQ: MDGL ) just reported results for the first quarter of 2024. Madrigal Pharmaceuticals reported earnings per share of -$7.38. This was belo...

2024-05-07 11:24:02 ET Madrigal Pharmaceuticals (MDGL) Q1 2024 Results Conference Call May 07, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler...

2024-05-07 10:44:37 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...

2024-05-07 07:04:22 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis In April 2024, product shipped and first patients received Rezdiffra, the first and ...

2024-05-06 11:08:27 ET Major earnings expected before the bell on Tuesday include: BP p.l.c. ( BP ) Datadog ( DDOG ) The Walt Disney ( DIS ) Duke Energy ( DUK ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...

2024-05-06 10:57:03 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...